Halozyme, Inc. v. Merck Sharp and Dohme LLC

I'll research this case across multiple sources before drafting.

Case Overview & Background — Halozyme, Inc. v. Merck Sharp & Dohme LLC, No. 2:25-cv-03179-ES-JRA (D.N.J.)

The parties. Halozyme, Inc. is a San Diego–based, Nasdaq-listed biotechnology operating company (a wholly owned subsidiary of Halozyme Therapeutics, Inc. (HALO)) whose core business is recombinant human hyaluronidase (rHuPH20/Hylenex®) and the ENHANZE® drug-delivery licensing platform; it is a practicing innovator with a large royalty-generating licensing program, not an NPE or PAE, and in the PTAB it describes itself as earning "more than a billion dollars every year" from ENHANZE® (Halozyme/PR Newswire; Merck PGR reply, PGR2025-00006 Paper 28). The defendant is Merck Sharp & Dohme LLC, the New Jersey–based U.S. human-health subsidiary of Merck & Co., Inc.; note that the complaint as filed named "Merck Sharp & Dohme Corp.," an entity that ceased to exist when it merged into the LLC in spring 2022, and the parties stipulated to substitute the LLC and reset the response date (undersigned as Dkt. 8; see the May 13, 2025 counsel correspondence reproduced as an exhibit in PGR2025-00039, Docket Alarm). Local counsel of record are Walsh Pizzi O'Reilly Falanga (Liza M. Walsh) for Halozyme, with Quinn Emanuel attorneys (David A. Nelson et al.) admitted pro hac vice, and Gibbons (Michael V. Caracappa) and Dechert for Merck (Law.com Radar; Dkts. 22–29, Justia docket).

The accused product and the patents. The accused product is Merck's subcutaneous pembrolizumab — approved by FDA in September 2025 and marketed in the U.S. as Keytruda Qlex™ (pembrolizumab; berahyaluronidase alfa‑pmph) — which pairs IV Keytruda with a modified PH20 hyaluronidase (berahyaluronidase alfa, also referred to as ALT‑B4, sourced from Alteogen) to permit rapid high‑volume subcutaneous injection. Halozyme's April 24, 2025 complaint (Dkt. 1) asserts 15 patents from its "MDASE™" family — U.S. 10,865,400; 11,041,149; 11,066,656; 11,952,600; 12,018,298; 12,037,618; 12,049,652; 12,054,758; 12,091,692; 12,104,185; 12,110,520; 12,152,262; 12,077,791; 12,195,773; and 12,264,345 — all tracing to 2011–2012 priority filings and all directed at modified human PH20 polypeptides, formulations containing them, and methods of use; the complaint alleges the enzyme in Keytruda Qlex embodies the very amino‑acid substitutions Halozyme's inventors identified, seeks damages plus an injunction, and pleads willfulness based on Merck's pre‑suit knowledge and its PGR campaign (complaint reproduced at STAT). The '692 patent (Count 10) is representative of the genus: issued September 17, 2024 from Application 17/327,568 (filed May 21, 2021, a continuation in a long chain back to U.S. Provisional 61/631,313, filed Dec. 30, 2011), titled "PH20 Polypeptide Variants, Formulations and Uses Thereof," and claims modified PH20 polypeptides having at least one amino‑acid substitution at position 313, ≥91% sequence identity to a reference PH20, and up to dozens of further substitutions — i.e., a very large structural genus said to retain hyaluronidase activity (PGR2025-00046 FWD; patent record). Note that the '692 is one of the later-issued "staircase" continuations — a deliberate strategy of layering new claims over the same 2011–2012 disclosure, which is central to both the infringement and validity fight.

Posture, venue and why it matters. The case sits in the District of New Jersey before U.S. District Judge Esther Salas, with Magistrate Judge Jose R. Almonte handling scheduling (the "-ES-JRA" suffix); an initial scheduling conference was held October 20, 2025 after a letter-order extension (Dkts. 31–33, Justia). Venue is essentially Merck's home forum (MSD is headquartered in Rahway/Kenilworth, N.J.), which forecloses a transfer fight, but it also means slow time-to-trial: Merck told the PTAB that D.N.J.'s median ~60-month time to trial implies a trial around May 2030, a fact the Director relied on in declining discretionary denial of the PGRs (PGR2025-00006 Paper 29, cited in PGR2025-00046 petition). That timing explains the case's defining feature: it is being fought to a large degree at the PTAB. Merck filed PGRs on 15 of the patents beginning in November 2024 — before the suit — 14 were instituted and one denied institution (May 15, 2026), and Merck added three IPRs in March 2026 covering patents that are not PGR-eligible (e.g., IPR2026-00312 on the '400 patent); the Board has

Bottom line

For U.S. Patent No. 12,091,692 (the '692 patent, Count 10 of the D.N.J. complaint), the case has not travelled the normal district-court path. There has been no Markman, no summary judgment practice, no trial, and no stay order that I can verify. The only merits adjudication of the '692 patent has occurred at the PTAB, where Merck's PGR (PGR2025-00046) was instituted on 2025‑10‑10 and culminated in a final written decision on 2026‑10‑02 holding all remaining challenged claims unpatentable under § 112(a). The D.N.J. action remains pending as of 2026‑11‑01, effectively parked while the patent-office record develops.

A caveat on sourcing: the D.N.J. docket itself is not freely accessible to me, and my search budget was exhausted before I could pull the answer/counterclaim document or confirm whether any stay motion has been filed. Where a fact is inferred rather than confirmed, I say so.

---

Chronology — '692 patent and the D.N.J. action

1. Patent issuance and the PGR window (2024)

• 2024‑09‑17 — The '692 patent issues from U.S. App. 17/327,568 (filed 2021‑05‑21), a continuation in a long chain back to App. 13/694,731 (filed 2012‑12‑28, now U.S. 9,447,401) and provisionals 61/631,313 (2011‑12‑30) and 61/796,208 (2012‑11‑01). Title: "PH20 polypeptide variants, formulations and uses thereof." (PTAB FWD in PGR2025-00046, § I.D.)
• 2024‑11 onward — Merck begins filing PGR petitions against Halozyme's MDASE/PH20 family; ultimately 14–15 petitions filed between November 2024 and November 2025, plus three IPRs in March 2026. (Pearce IP/Lexology, 2025‑11‑19; updated 2026‑05‑12 table)
• Because the '692 patent issued 2024‑09‑17, its nine-month PGR eligibility window closed around 2025‑06‑17 — a deadline Merck had to beat and did.

2. Complaint (2025‑04‑24)

• 2025‑04‑24 — Halozyme files Halozyme, Inc. v. Merck Sharp & Dohme Corp., No. 2:25‑cv‑03179‑ES‑JRA (D.N.J.) (Doc. 1, 50 pp.), assigned to U.S. District Judge Esther Salas. The complaint asserts 15 patents; the '692 patent appears as Count 10.
• Theories pleaded: direct/indirect infringement by SC Keytruda (later branded Keytruda Qlex), **will

I'll research the counsel of record for Halozyme in this case.

Good leads. Let me dig into the D.N.J. appearances specifically.

Important finding — Quinn Emanuel attorneys appear as "Attorneys for Plaintiff." Let me verify the docket and complaint signature block.

I'll research the counsel of record for Merck Sharp and Dohme LLC in this case.

Let me dig into the docket entries and specific attorney appearances.

Now let me look for the actual docket sheet and Gibbons' local counsel team.

Counsel of Record for Defendant Merck Sharp & Dohme LLC

Bottom line: Merck is represented by a two-firm team — Dechert LLP as national/lead patent counsel and Gibbons P.C. (Newark) as New Jersey local counsel. Appearances were entered on May 20, 2025 (ECF Nos. 9–11) and pro hac vice admissions were granted May 23, 2025 (ECF No. 13), i.e., within about a month of filing and immediately after the May 15, 2025 stipulation substituting Merck Sharp & Dohme LLC for the (non-existent) "Merck Sharp & Dohme Corp." (ECF No. 8). This is consistent with the Law.com Radar entry identifying "Gibbons, Dechert" as defendant counsel.

Confirmed appearances on the D.N.J. docket (2:25-cv-03179-ES-JRA)

In-house

• Mark Stewart (mark.stewart@merck.com) appears as back-up counsel for Merck in the parallel PTAB post-grant reviews (PGR2025-00003 through -00087), where his listed "firm name" with the USPTO OED is Merck Sharp & Dohme, LLC / Merck & Co. — a fact Halozyme has attacked in its real-party-in-interest discovery motion. I could not confirm that Stewart has entered an appearance in the district court case; I would not list him as counsel of record in D.N.J. without that confirmation.

Notes, caveats and gaps

• No sealed-appearance issue: the appearances and the answer are public docket entries; nothing about Merck's representation is under seal. The filings that are likely sealed or redacted are substantive (infringement/invalidity contentions, damages), not the identity of counsel.
• Docket snapshot limitation: the most recent entry I could verify is ECF No. 31 (Aug. 27, 2025 — amended Rule 16.1 letter order setting an initial scheduling conference for Oct. 20, 2025 before Magistrate Judge Jose R. Almonte). Additional Dechert or Gibbons appearances may have been added after that date (e.g., for claim construction or expert discovery) that I could not verify; treat the table as complete through late August 2025.
• Firm naming: a third-party attorney database lists Caracappa's firm as "FBT Gibbons LLP," which is consistent with a reported Frost Brown Todd–Gibbons combination. The docket and the May 2025 correspondence use Gibbons P.C. and the gibbonslaw.com domain. I have not independently verified the merger's effective date or the firm's current formal name — flag as unverified.
• Section 1782 / global coordination: Helm's own public bios describe her as routinely running coordinated U.S./European disputes, which fits the parallel German (Munich PI, 7 O 12286/25), Dutch (The Hague, C/09/695432), and UK (HP-2025-000041) proceedings against the same subcutaneous-Keytruda product. Whether Dechert coordinates with Merck's European counsel of record (Hogan Lovells in the UK, per the EWHC judgment) is not documented in the sources I retrieved.
• Do not attribute Halozyme's counsel to Merck: Halozyme's team is separate — Walsh Pizzi O'Reilly Falanga (Newark) as local counsel, with Quinn Emanuel (David A. Nelson, Lauren Martin, et al., admitted PHV per ECF Nos. 20–23) and Russ August & Kabat / Irell-type PTAB counsel on the patent-owner side; Payne-type confusion between the two teams is a common error in secondary coverage.